Skip to content
value.today
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc.

OTLK
$119 Mmarket cap on Oct 30, 2026+9.4% since Jan 2024
Compare
World rank
#18,103
Revenue
$1 M
For year ending September-2025
Net income
$-62 M
-4427.0% margin
SEC filing
Employees
—

Outlook Therapeutics, Inc. in brief

Outlook Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Iselin, New Jersey, USA. Its market value was $119 M on 30 October 2026, which makes it the 18,103rd largest listed company in the world and the 3,429th largest in the USA on this site. In the year to September 2025 it had sales of $1 M and a net loss of $62 M. Robert Charles Jahr is its chief executive. Its largest business segments by sales in 2025 were Development and commercialization of ONS-5010/LYTENAVA (100%). Its shares trade under the symbol OTLK (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. is a late clinical stage biopharmaceutical company. The company total assets are 19.7 million USD as on 2020. The headquarters is in USA.

Outlook Therapeutics, Inc. timeline

4 events, 2015–2019
  1. 2015
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2016
  4. 🔔
    Initial public offering as Oncobiologics, Inc.
    Final prospectus filed with the SEC on 13 May 2016; shares registered for exchange trading on 11 May 2016.
  5. 2018
  6. ✎
    Renamed Outlook Therapeutics, Inc.
    Formerly Oncobiologics, Inc..
  7. 2019
  8. 💰
    Record revenue of $8 million
    FY2019, the highest of the 3 years on record.

Events of Outlook Therapeutics, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$114 M$228 M$342 M$456 M2023202420252026

World rank over time

▼ down 1,312 places since 2022
2022-01-07: #16826#16,82620222022-12-25: #18033#18,03320222023-07-30: #13829#13,82920232024-01-05: #20958#20,95820242026-03-08: #11453#11,45320262026-08-01: #16393#16,39320262026-10-14: #17687#17,68720262026-10-30: #18138#18,1382026

Rank in USA: #3,490 (Jan 2022) · #3,676 (Dec 2022) · #2,845 (Jul 2023) · #3,633 (Jan 2024) · #2,225 (Mar 2026) · #3,267 (Aug 2026) · #3,327 (Oct 2026) · #3,432 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
84.6×
Price / book
—
Free cash flow yield
-27.4%
Net margin
-4427.0%
Operating margin
-4756.0%
Return on equity
—
Liabilities / assets
273.3%
Net debt
$1.1B
Revenue growth
-82.7%
R&D / revenue
1927.7%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Sep 2018: revenue $3M, net income $-30M$3MFY18Fiscal year ending Sep 2019: revenue $8M, net income $-35M$8MFY19Fiscal year ending Sep 2020: revenue —, net income $-35M—FY20Fiscal year ending Sep 2021: revenue —, net income $-53M—FY21Fiscal year ending Sep 2022: revenue —, net income $-66M—FY22Fiscal year ending Sep 2023: revenue —, net income $-59M—FY23Fiscal year ending Sep 2024: revenue —, net income $-75M—FY24Fiscal year ending Sep 2025: revenue $1M, net income $-62M$1MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Sep 2025$1M—$-67M$-62M-4427.0%
Sep 2024——$-72M$-75M—
Sep 2023——$-53M$-59M—
Sep 2022——$-63M$-66M—
Sep 2021——$-52M$-53M—
Sep 2020——$-37M$-35M—
Sep 2019$8M+163.8%$-36M$-35M-423.6%
Sep 2018$3M—$-30M$-30M-973.8%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Sep 2025$-52M——$-1.79—
Sep 2024$-69M——$-4.06—
Sep 2023$-43M——$-4.72—
Sep 2022$-57M——$-0.31—
Sep 2021$-54M——$-0.35—
Sep 2020$-32M——$-0.67—
Sep 2019$-32M$0M$-33M$-1.98—
Sep 2018$-33M$3M$-36M$-1.22—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Sep 2024 (from the annual report): revenue —, net income $6M—Sep ’24Three months to Dec 2024: revenue —, net income $17M—Dec ’24Three months to Mar 2025: revenue —, net income $-46M—Mar ’25Three months to Jun 2025: revenue $2M, net income $-20M$2MJun ’25Three months to Sep 2025 (from the annual report): revenue —, net income $-13M—Sep ’25Three months to Dec 2025: revenue —, net income $-23M—Dec ’25Three months to Mar 2026: revenue —, net income $-4M—Mar ’26Three months to Jun 2026: revenue —, net income $-20M—Jun ’26

Latest quarter to Jun 2026: revenue —, net income $-20M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Outlook Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$1 M
Operating income
$-67 M
Net income
$-62 M

For year ending September-2025 · source: SEC filing

Balance sheet

Total assets
$19 M
Total liabilities
$51 M
Total equity
$-32 M

As of September-2025

Top 82 institutional investors in Outlook Therapeutics, Inc.#

As of Sep 30, 2026
82 institutions held 63.5 M shares (about 26.1% of the shares outstanding) on Sep 30, 2026. The ten largest hold 23.1%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Outlook Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Empery Asset Management, LP21,247,856New8.73%$12 MNov 16, 2026
2Vanguard Capital Management LLC8,976,833+4,599,961 (+105.10%)3.69%$5 MNov 13, 2026
3Marshall Wace, LLP8,023,703+6,036,125 (+303.69%)3.30%$5 MNov 13, 2026
4Ameriprise Financial Inc5,050,505New2.07%$3 MNov 16, 2026
5UBS Group AG3,343,234+3,191,019 (+2096.39%)1.37%$2 MNov 10, 2026
6Perceptive Advisors LLC3,139,2160 (0.00%)1.29%$2 MNov 16, 2026
7Geode Capital Management, LLC1,716,408+470,540 (+37.77%)0.70%$1 MNov 6, 2026
8BlackRock, Inc.1,667,775-804 (-0.05%)0.69%$1 MNov 13, 2026
9Two Sigma Investments, LP1,634,105New0.67%$1 MNov 16, 2026
10Susquehanna International Group, LLP1,422,923+454,733 (+46.97%)0.58%$1 MNov 16, 2026
11Renaissance Technologies LLC1,120,688New0.46%$1 MNov 12, 2026
12Vanguard Fiduciary Trust Co1,067,919+406,255 (+61.40%)0.44%$1 MNov 13, 2026
13Gilpin Wealth Management, LLC625,000+70,000 (+12.61%)0.26%$0 MOct 9, 2026
14State Street Corp569,702+29,900 (+5.54%)0.23%$0 MNov 12, 2026
15Northern Trust Corp409,661+172,100 (+72.44%)0.17%$0 MNov 16, 2026
16Hudson Bay Capital Management LP383,687New0.16%$0 MNov 13, 2026
17Gsa Capital Partners LLP368,909New0.15%$0 MNov 16, 2026
18Raymond James Financial Inc332,0510 (0.00%)0.14%$0 MNov 12, 2026
19Citigroup Inc221,657+220,892 (+28874.77%)0.09%$0 MNov 4, 2026
20Cantor Fitzgerald, L. P.220,513-229,487 (-51.00%)0.09%$0 MNov 16, 2026
21Persistent Asset Partners Ltd198,655New0.08%$0 MNov 13, 2026
22WINTON GROUP Ltd188,282New0.08%$0 MNov 12, 2026
23Jane Street Group, LLC158,648-1,266,622 (-88.87%)0.07%$0 MNov 12, 2026
24Citadel Advisors LLC138,818New0.06%$0 MNov 16, 2026
25Tudor Investment Corp Et Al132,217New0.05%$0 MNov 16, 2026
Show all 82: investors 26 to 82
Institutional investors 26 to 82 in Outlook Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Royal Fund Management, LLC111,415+64,215 (+136.05%)0.05%$0 MOct 22, 2026
27Jefferies Financial Group Inc.62,5000 (0.00%)0.03%$0 MNov 5, 2026
28NewEdge Advisors, LLC60,669+43,947 (+262.81%)0.02%$0 MNov 13, 2026
29LPL Financial LLC54,283-130,659 (-70.65%)0.02%$0 MNov 6, 2026
30Christensen, King & Associates Investment Services, Inc.54,066+25,739 (+90.86%)0.02%$0 MOct 22, 2026
31Corient Private Wealth LP50,300New0.02%$0 MNov 16, 2026
32MAI Capital Management50,000New0.02%$0 MNov 12, 2026
33Flower City Capital50,000+30,000 (+150.00%)0.02%$0 MOct 15, 2026
34Morgan Stanley45,069+28,113 (+165.80%)0.02%$0 MNov 13, 2026
35Vanguard Global Advisers, LLC41,1370 (0.00%)0.02%$0 MNov 13, 2026
36Harbour Investments, Inc.40,812+28,508 (+231.70%)0.02%$0 MNov 9, 2026
37Group One Trading LLC36,349-210,079 (-85.25%)0.01%$0 MNov 10, 2026
38Warberg Asset Management LLC35,177New0.01%$0 MNov 2, 2026
39Diadema Partners LP35,000New0.01%$0 MNov 16, 2026
40Cerity Partners LLC34,691New0.01%$0 MNov 13, 2026
41Scotia Capital Inc.26,300-20,000 (-43.20%)0.01%$0 MNov 10, 2026
42Jpmorgan Chase & Co26,215+18,245 (+228.92%)0.01%$0 MNov 12, 2026
43PNC Financial Services Group, Inc.25,0000 (0.00%)0.01%$0 MNov 6, 2026
44Optiver Holding B.V.21,332New0.01%$0 MNov 16, 2026
45Clearwater Capital Advisors, LLC20,000New0.01%$0 MNov 6, 2026
46Engineers Gate Manager LP19,953New0.01%$0 MNov 16, 2026
47Bank of New York Mellon Corp18,6640 (0.00%)0.01%$0 MNov 5, 2026
48Cora Capital Advisors LLC18,000New0.01%$0 MNov 2, 2026
49FSA Advisors, Inc.16,898New0.01%$0 MNov 10, 2026
50Oppenheimer & Co Inc16,500+2,500 (+17.86%)0.01%$0 MOct 26, 2026
51HighTower Advisors, LLC16,425New0.01%$0 MNov 10, 2026
52Vanguard Personalized Indexing Management, LLC15,716-8,403 (-34.84%)0.01%$0 MNov 16, 2026
53Orrstown Financial Services Inc15,0000 (0.00%)0.01%$0 MOct 14, 2026
54Creative Planning13,693New0.01%$0 MNov 2, 2026
55Goldman Sachs Group Inc13,671New0.01%$0 MNov 16, 2026
56Simplicity Wealth,LLC13,310+2,000 (+17.68%)0.01%$0 MOct 23, 2026
57Fifth Third Wealth Advisors LLC10,0000 (0.00%)0.00%$0 MOct 22, 2026
58Osaic Holdings, Inc.9,063-2,403 (-20.96%)0.00%$0 MNov 12, 2026
59Jacobi Capital Management LLC8,080New0.00%$0 MNov 5, 2026
60Rockefeller Capital Management L.P.8,000+1,750 (+28.00%)0.00%$0 MNov 13, 2026
61Bullock Wealth Management Group7,112+3,000 (+72.96%)0.00%$0 MOct 9, 2026
62GoalVest Advisory LLC3,0000 (0.00%)0.00%$0 MOct 2, 2026
63Jones Financial Companies Lllp2,5000 (0.00%)0.00%$0 MNov 13, 2026
64Northwestern Mutual Wealth Management Co2,1250 (0.00%)0.00%$0 MNov 13, 2026
65Deutsche Bank AG\2,000-128,700 (-98.47%)0.00%$0 MNov 6, 2026
66Global Retirement Partners, LLC1,5000 (0.00%)0.00%$0 MNov 10, 2026
67Fortitude Family Office, LLC1,4290 (0.00%)0.00%$0 MOct 14, 2026
68Wells Fargo & Company/mn1,4100 (0.00%)0.00%$0 MNov 16, 2026
69Nuveen, LLC1,152New0.00%$0 MNov 10, 2026
70Ancora Advisors LLC1,1000 (0.00%)0.00%$0 MNov 17, 2026
71SBI Securities Co., Ltd.511+289 (+130.18%)0.00%$0 MOct 22, 2026
72EverSource Wealth Advisors, LLC363-333 (-47.84%)0.00%$0 MNov 4, 2026
73Royal Bank Of Canada241+85 (+54.49%)0.00%$0 MNov 16, 2026
74Armstrong Advisory Group, Inc1790 (0.00%)0.00%$0 MOct 9, 2026
75BNP Paribas Financial Markets177-128 (-41.97%)0.00%$0 MNov 12, 2026
76Larson Financial Group LLC1000 (0.00%)0.00%$0 MNov 5, 2026
77Prestige Wealth Management Group LLC620 (0.00%)0.00%$0 MNov 16, 2026
78Barclays PLC61New0.00%$0 MNov 6, 2026
79BFC Planning, Inc.610 (0.00%)0.00%$0 MNov 13, 2026
80Federation des caisses Desjardins du Quebec250 (0.00%)0.00%$0 MNov 16, 2026
81Bogart Wealth, LLC50 (0.00%)0.00%$0 MNov 10, 2026
82FMR LLC10 (0.00%)0.00%$0 MNov 10, 2026

Mutual funds holding Outlook Therapeutics, Inc.#

9 funds hold shares worth $7 M (about 3.4% of the company). Since their previous reports 7 added shares and 2 sold, buying $4 M net.
Mutual funds holding Outlook Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.3.07 M$5 M2.2%<0.01%+226%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.1.23 M$2 M0.87%<0.01%+20%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC382,684$0 M0.27%<0.01%+138%May 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.46,106$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.29,620$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC57,557$0 M0.04%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC52,929$0 M0.04%<0.01%+31%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC7,574$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC603$0 M<0.01%<0.01%+91%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 9 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Outlook Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$7.9 M
10 purchases, 8 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$7.9 M
open market only
Insiders on file
24
since
$5.3 M$0Mar 2024: bought $48 K (2 trades), sold $0 (0 trades)Mar 24Apr 2024: bought $0 (1 trades), sold $0 (0 trades)AprSep 2024: bought $28 K (1 trades), sold $0 (0 trades)SepMay 2026: bought $5.3 M (5 trades), sold $0 (0 trades)MayJun 2026: bought $24 K (1 trades), sold $0 (0 trades)JunJul 2026: bought $100 K (1 trades), sold $0 (0 trades)JulAug 2026: bought $2.5 M (3 trades), sold $0 (0 trades)Aug
Bought (open market)Sold (open market)Hover a month for the totals
Outlook Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Lawrence A. KenyonChief Financial Officer, DirectorBuy+101,010——106,956Form 4
filed Robert Charles JahrChief Executive Officer, DirectorBuy+151,515——151,515Form 4
filed Ghiath M. SukhtianDirector, 10% ownerBuyindirect+2.53 M$0.990$2.5 M24.62 MForm 4
filed Faisal Ghiath SukhtianDirectorBuy+95,398$1.050$100 K220,972Form 4
filed Yezan Munther HaddadinDirectorBuy+29,000$0.830$24 K66,167Form 4
filed GMS Ventures & InvestmentsDirector, 10% ownerBuyindirect+8.54 M$0.590$5.0 M22.09 MForm 4
filed Faisal Ghiath SukhtianDirectorBuy+122,174$0.410$50 K125,574Form 4
filed Kurt J. HilzingerDirectorBuy+400,000$0.440$176 K423,655Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Outlook Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
35.5 M
66.0% of shares · 10.1 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-20 reverse split ; 1-for-8 reverse split

Trading halts

  • 2026-07-24 19:00 UTC, code LUDP, resumed 19:05 UTC
  • 2026-07-24 17:34 UTC, code T3, resumed 19:00 UTC
  • 2025-12-31 21:10 UTC, code T3, resumed 21:35 UTC
  • 2024-11-27 16:31 UTC, code LUDP, resumed 16:36 UTC
  • 2024-11-27 15:56 UTC, code LUDP, resumed 16:01 UTC

Fails to deliver

  • : 636,933 shares at $0.49
  • : 192,078 shares at $0.54
  • : 61,859 shares at $0.53
  • : 12,252 shares at $0.56
  • : 29,959 shares at $0.56

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Outlook Therapeutics, Inc. scorecard#

Passes 0 of the 13 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • ✗Price to sales below its peers' median84.6×Price to sales 84.6× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-27.4%Free cash flow is -27.4% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.79 vs -4.06Diluted EPS -1.79 in fiscal 2025 against -4.06 the year before (report's currency).
    • ✗Net income higher than five years earlier-$62 M-$62 M in fiscal 2025 against -$35 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$62 MNet income -$62 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health0 of 3
    • ✗Short-term assets cover short-term liabilities0.4×Current ratio 0.38 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-57.90Z-score -57.90 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year87.6%Diluted shares up 87.6% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Outlook Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Outlook Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Sep 30, 2025FY 2024to Sep 30, 2024FY 2023to Sep 30, 2023FY 2022to Sep 30, 2022FY 2021to Sep 30, 2021FY 2020to Sep 30, 2020FY 2019to Sep 30, 2019FY 2018to Sep 30, 2018FY 2017to Sep 30, 2017FY 2016to Sep 30, 2016
Income statement
Revenue1.4—————8.13.13.83.0
Cost of revenue1.4—————————
Gross profit0.1—————————
Research and development27422642392624192433r
Selling, general and administrative4030————————
General and administrative—3027211310.09.4141622r
Operating expenses————523744334054r
Operating income−67−72−53−63−52−37−36−30−36−51r
Interest and finance income0.10.91.0———————
Interest expense and finance costs—3.22.5——1.83.53.95.61.9r
Net interest income−0.3−3.2−1.6−1.5−0.9−1.8————
Share of profit of associates−0.1−0.1−0.0−0.0−0.0—————
Income before tax−64−75−59−66−53−39−38−34−38−53r
Income tax−1.60.00.00.00.0−3.3−3.4−3.60.50.1
Net income including minority interests—————————−53
Net income attributable to shareholders−62−75−59−66−53−35−35−30−39−53r
Earnings per share, basic-1.79-4.06-4.72r-0.31-0.35-0.67-1.98-1.22-1.67-3.67
Earnings per share, diluted-1.79-4.06-4.72r-0.31-0.35-0.67-1.98-1.22-1.80-3.67
Shares, weighted average (basic)351913r21215373—392417
Shares, weighted average (diluted)351913r2121537318392417
Balance sheet
Cash and cash equivalents8.115231714138.01.73.22.4
Receivables1.5—————————
Inventory3.3—————————
Other current assets4.5127.6107.05.45.01.60.73.3
Current assets172731282218143.33.95.7
Property, plant and equipment————0.20.33.2181619r
Right-of-use (leased) assets0.20.30.00.10.10.2————
Investments in associates0.60.70.80.80.9—————
Total assets19293229232017222125r
Accounts payable108.06.63.52.22.42.33.6115.1
Debt due within a year——————1,026r0.10.10.6
Current liabilities464347206.81620322920
Long-term debt——————50r0.10.22.2
Lease liabilities (non-current)0.20.2——0.0—————
Total liabilities511024720181728435131r
Retained earnings−606−543−468−409−343−290−254−216−186−147r
Shareholders' equity−32−73−148.74.62.8−16−26−34−5.2r
Total equity—————————−5.2
Total liabilities and equity19293229232017222125r
Shares outstanding542413r227176127299.0r2523
Cash-flow statement
Depreciation and amortization0.10.10.00.20.30.23.43.1r2.72.4
Share-based compensation8.95.45.57.74.92.81.32.08.612
Cash from operating activities−52−69−43−57−54−32−32−33−16−45
Capital expenditure——————−0.4−2.8−0.3−1.1
Cash from investing activities—————−0.9−0.4−2.8−0.3−1.1
Debt issued33—3010100.9———0.2
Debt repaid−36—−10−12−0.1−0.0−6.4−0.1−2.7−1.1
Shares issued25603062463546151.616
Cash from financing activities45604960563739341740
Change in cash−6.8−8.56.02.91.94.56.3−1.50.8−6.7
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Outlook Therapeutics, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • Development and commercialization of ONS-5010/LYTENAVA$1 M100%

Source: SEC annual report (XBRL data) · as of Sep 30, 2025

Where Outlook Therapeutics, Inc. operates: 7 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 6 subsidiaries on file.

Outlook Therapeutics, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office—
🇦🇺 Australia1 subsidiary—
🇩🇪 Germany1 subsidiary—
🇮🇪 Ireland1 subsidiary—
🇳🇱 Netherlands1 subsidiary—
🇨🇭 Switzerland1 subsidiary—
🇬🇧 UK1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Events at Outlook Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 3 · Directors and officers 4 · Material agreement 2 · Agreement ended 1 · New debt 1 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 6

Outlook Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Delisting notice8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Bylaws or fiscal year changedShareholder vote8-K
Delisting notice8-K
Results announced8-K
Material agreementAgreement endedResults announced8-K
Unregistered share sale8-K
Material agreementNew debt8-K
Directors and officers8-K
Shareholder vote8-K
Delisting notice8-K
Results announced8-K
Results announced8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Sep 30, 2026

Acquisitions and funding#

3 private funding rounds before listing

Private share sales · funding history

Private share sales of Outlook Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2024$5 MPrivate placement after listing$2 to $10 million1equity, optionsSEC
Mar 2024$60 MPrivate placement after listing$50 to $250 million21equity, optionsSEC
Dec 2022$1 MPrivate placement after listingUnder $2 million1optionsSEC
Feb 2021$4 MPrivate placement after listing$2 to $10 million2equitySEC
Jun 2020$16 MPrivate placement after listing$10 to $50 million1equitySEC
Feb 2020$8 MPrivate placement after listing$2 to $10 million7equity, optionsSEC
Sep 2017$3 MPrivate placement after listing$2 to $10 million1equity, optionsSEC
Dec 2015$6 MNo. 3$2 to $10 million11equitySEC
Sep 2015$14 MNo. 2$10 to $50 million4equitySEC
Jun 2015$31 MNo. 1$10 to $50 million7equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

FDA drug approvals: Outlook Therapeutics, Inc.#

1 approved applications held, 1 of them new molecular entities; 1 approvals and 0 new uses in 2026.

Approvals held
1
New molecular entities
1
New uses approved
0
efficacy supplements
Generics
0
0 new drugs, 1 biologics
Outlook Therapeutics, Inc.: latest FDA approvals
ApprovedDrugKind
2026-07-24Lytenavanew moleculeBevacizumab-Vikg · BLA761320Biologic (BLA)

Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (OUTLOOK THERAPEUTICS, INC.), so they follow acquisitions

Layoffs at Outlook Therapeutics, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
5
2024–2024
Latest
5 people
2024-12-10
Outlook Therapeutics, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2024···········55
Outlook Therapeutics, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
5 people (23% of workforce)Restructuring planSEC 8-K“On December 13, 2024, the Company reduced its workforce by 5 people, or approximately 23% of the Company’s existing headcount.”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Outlook Therapeutics, Inc. compares in Biotechnology

  • Market cap$119 M · higher than 38% of 726
  • Revenue$1 M · higher than 28% of 647
  • Price / sales84.6× · lower than 12% of 339
  • FCF yield-27.4% · higher than 35% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Outlook Therapeutics, Inc.🇺🇸$119 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending September-2025
Balance sheet:
As of September-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Outlook Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Outlook Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Outlook Therapeutics, Inc.? Suggest a correction